tegafur has been researched along with gimeracil in 83 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (8.43) | 18.2507 |
| 2000's | 23 (27.71) | 29.6817 |
| 2010's | 40 (48.19) | 24.3611 |
| 2020's | 13 (15.66) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, T; Hirota, T; Irimura, K; Ohmae, S; Tanaka, G | 1 |
| Kouchi, Y; Maeda, Y; Ohuchida, A; Sato, S | 1 |
| Kitamura, R; Matsushima, E; Yoshida, K | 1 |
| Taguchi, T | 1 |
| Meropol, NJ | 1 |
| Adjei, AA | 1 |
| Horikoshi, N; Maehara, Y; Mitachi, Y; Sakata, Y; Shimada, Y; Sugimachi, K; Taguchi, T | 1 |
| Hironaga, K; Kawaguchi, Y; Nagayama, S; Yamaguchi, S; Yamamoto, A; Yoshisue, K | 1 |
| Kawaguchi, Y; Komatsu, T; Nagayama, S; Nakajima, M; Shimada, N; Yamazaki, H; Yokoi, T | 1 |
| Kawaguchi, Y; Nagayama, S; Shindo, T; Yoshisue, K | 1 |
| Ichiro, M; Iwahashi, M; Nakamori, M; Nakamura, M; Nishino, E; Sakaguchi, S; Tani, M; Tanimura, H; Ueda, K; Yamaue, H | 1 |
| Ariyoshi, N; Daigo, S; Fujieda, M; Ikeda, K; Kamataki, T; Koizumi, W; Nagayama, S; Nishioka, Y; Saigenji, K; Takahashi, Y; Tanabe, S; Yamazaki, H | 1 |
| Malet-Martino, M; Martino, R | 1 |
| Schöffski, P | 1 |
| Fujioka, A; Fukushima, M; Ikeda, K; Kitazato, K; Nakagawa, F; Ohshimo, H; Okabe, H; Takechi, T | 1 |
| Fujita, S; Okajima, S; Ooka, M; Tanaka, N; Tanaka, T | 1 |
| Kamano, T; Kawai, K; Kitajima, M; Ochiai, T; Sakamoto, K; Shirasaka, T; Tsuruoka, Y; Watabe, S | 1 |
| Hatori, S; Imada, T; Kunisaki, C; Oshima, T; Yamada, R | 1 |
| Hori, S; Inoue, S; Ohtani, H; Sawada, Y; Tsujimoto, M | 1 |
| Aizaki, K; Fujii, M; Kaiga, T; Kanamori, N; Kochi, M; Takahashi, T; Takayama, T | 1 |
| Bang, YJ; Choi, IS; Heo, DS; Im, SA; Kim, DW; Kim, HG; Kim, JH; Kim, SW; Kim, TY; Kim, YJ; Lee, KW; Lee, SH; Oh, DY; Oh, SY; Yoon, YB | 1 |
| Fujiyama, J; Hori, S; Miki, A; Ohtani, H; Sawada, Y; Tsuda, A | 1 |
| Aoyama, I; Arai, O; Doi, A; Hata, T; Hirao, K; Jinno, A; Katayama, S; Kikuchi, O; Kiyosuke, Y; Maeda, Y; Matsueda, K; Miyoshi, M; Mouri, H; Sakai, A; Tanabe, W; Terashima, Y; Tsuji, Y; Yamamoto, H; Yamamoto, N | 1 |
| Akiyama, Y; Ando, Y; Araki, K; Endo, H; Endo, S; Fujita, K; Ichikawa, W; Kamataki, T; Kawara, K; Kodama, K; Miwa, K; Miya, T; Nagashima, F; Narabayashi, M; Sasaki, Y; Sunakawa, Y; Tanaka, R; Yamamoto, W | 1 |
| Kono, T; Noguchi, T; Nohara, J; Sakaguchi, Y; Terada, Y | 1 |
| Dai, GH; Jiao, SC; Li, F; Li, Y; Liu, W; Lu, HS; Niu, RG; Song, SP; Wang, J; Xie, XD; Xu, JM; Yang, JL; Zhang, FC; Zhang, Y; Zhao, H | 1 |
| Hanauske, A; Hilger, RA; Krauss, J; Kredtke, S; Makris, L; Mende, B; Scheulen, ME; Scigalla, P; Strumberg, D; Thyssen, D; Urrea, PD | 1 |
| Akiyama, Y; Ando, Y; Araki, K; Endo, H; Fujita, K; Hirose, T; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Miya, T; Mizuno, K; Nagashima, F; Nakayama, H; Narabayashi, M; Sasaki, Y; Sunakawa, Y; Tanaka, R; Yamamoto, W; Yamashita, K | 1 |
| Cho, C; Choi, C; Kang, H; Kim, J; Kim, MS; Kim, Y; Lee, D; Seo, Y; Yang, K; Yoo, H; Yoo, S | 1 |
| Gu, Y; Liu, C; Lu, R; Si, D | 1 |
| Chen, X; Liu, K; Zhong, D; Zou, H | 1 |
| Asai, K; Honda, H; Nakamura, K; Nakashima, T; Nonoshita, T; Ohga, S; Ohnishi, K; Shioyama, Y; Terashima, K; Yoshitake, T | 1 |
| Atsumi, K; Higaki, Y; Hirata, H; Honda, H; Nakamura, K; Ohnishi, K; Ohura, H; Sasaki, T; Shinoto, M; Shioyama, Y; Toh, Y; Yamaguchi, T | 1 |
| Fukushima, M; Nakagawa, F; Saito, H; Sakamoto, K; Sakata, M; Sakata, Y | 1 |
| Akiyama, S; Goto, H; Hanibuchi, M; Kakiuchi, S; Kuramoto, T; Mitsuhashi, A; Nishioka, Y; Sato, S; Sone, S; Van, TT | 1 |
| Bou, H; Kanno, H; Kiyama, T; Maejima, K; Suzuki, H; Tokunaga, A; Uchida, E; Watanabe, M | 1 |
| Mendelson, DS; Ravage-Mass, L; Rosen, LS; Saif, MW; Saito, K; Zergebel, C | 1 |
| Jin, ZM; Zhu, QC | 1 |
| Abadie, E; Calvo Rojas, G; Camarero, J; Garcia-Carbonero, R; Matt, P; Pignatti, F; Ter Hofstede, H; van Zwieten-Boot, B | 1 |
| Bando, T; Chen, F; Date, H; Fujinaga, T; Miyahara, R; Sakai, H; Sato, T; Shoji, T; Sonobe, M; Wada, H | 1 |
| Ando, Y; Fujimoto, Y; Fujita, K; Hiramatsu, M; Inada, M; Kawada, K; Mitsuma, A; Morita, S; Yasuda, Y | 1 |
| Chu, Y; Ding, L; Liu, HY; Yu, Y; Zhu, H | 1 |
| Kawamura, M; Matsutani, N | 1 |
| Fujimura, Y; Himeno, A; Hirata, H; Inoue, K; Kida, H; Kijima, T; Kumanogoh, A; Matsumoto, M; Nagatomo, I; Nishijima, Y; Otani, Y; Tachibana, I; Takahashi, R; Takeda, Y | 1 |
| Atsumi, K; Hirata, H; Honda, H; Matsumoto, K; Nakamura, K; Nonoshita, T; Ooga, S; Sasaki, T; Shioyama, Y; Uehara, S; Yoshitake, T | 1 |
| Fueki, N; Hisada, T; Ishihara, S; Iwasaki, Y; Kaira, K; Kazama, T; Koga, Y; Kohyama, K; Minato, K; Miura, Y; Ono, A; Saito, R; Sato, K; Sunaga, N; Tomizawa, Y; Yoshii, A; Yoshino, R | 1 |
| Duh, D; Warnez, M | 1 |
| Hiraoka, N; Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Shimizu, S; Shoji, H; Ueno, H | 1 |
| Katolická, J; Rotnáglová, S; Vaníček, J | 1 |
| Haruma, K; Higashida, M; Hirai, T; Hiratsuka, J; Kubota, H; Matsumoto, H; Nakamura, M; Yoden, E | 1 |
| Ajiki, T; Eguchi, H; Fujiwara, Y; Hatano, E; Ioka, T; Kanai, M; Kobayashi, S; Kubo, S; Morita, S; Nagano, H; Sakai, D; Seo, S; Takemura, S; Taura, K; Terajima, H; Toyokawa, H; Tsuji, A; Yanagimoto, H | 1 |
| Lv, JQ; Wang, HF | 1 |
| Hwang, A; Ju Choi, I; Kim, MJ; Kim, YW; Lee, JH; Lim, HS; Park, SR; Park, YI; Ryu, KW | 1 |
| Andratschke, N; Duma, MN; Hadjamu, M; Oechsner, M; Schönknecht, C | 1 |
| Kurashima, Y; Miyazaki, T; Ohata, K; Ohno, K; Okawa, M; Tanaka, S; Uenishi, T; Yamamoto, T | 1 |
| Boku, N; Fuse, N; Kanato, K; Kato, K; Mizusawa, J; Muro, K; Nihei, K; Ohtsu, A; Sato, A; Tahara, M; Takaishi, H; Yamazaki, K | 1 |
| Eto, S; Higashijima, J; Hotchi, M; Iwata, T; Nakao, T; Nishi, M; Shimada, M; Takasu, C; Teraoku, H; Yoshikawa, K | 1 |
| Ren, J; Wei, H; Yang, ZH; Yi, LJ; Zheng, JH | 1 |
| Hui, H; Sun, S; Wan, Y; Wang, X; Wu, J | 1 |
| Koike, T; Nagasawa, A; Namura, O; Okamoto, T; Tsuchida, M | 1 |
| Aoe, M; Date, H; Fukuda, M; Hotta, K; Kajiwara, S; Kataoka, K; Kataoka, M; Matsuo, K; Nakamura, H; Nakata, M; Okumura, N; Sano, Y; Soh, J; Toyooka, S | 1 |
| Lee, ES; Park, YJ; Soh, BW | 1 |
| Fukayama, M; Hata, K; Ishihara, S; Kawai, K; Kiyomatsu, T; Morikawa, T; Nozawa, H; Watanabe, T | 1 |
| Hanafusa, T; Hashimoto, T; Matsuda, K; Namiki, T; Ueno, M; Yokozeki, H | 1 |
| Asada, H; Miyagawa, F; Sho, M; Sugano, Y | 1 |
| Bulitta, JB; Jeong, SW; Kim, TH; Kwon, DR; Min, BS; Park, GY; Shin, BS; Shin, JC; Shin, S; Weon, KY; Woo, MH; Yoo, SD | 1 |
| An, JY; Kim, S; Kim, SM; Lee, J; Sohn, TS | 1 |
| Doi, T; Okino, T; Sakamoto, T | 1 |
| Cho, K; Cho, S; Gwon, MR; Kang, WY; Kim, BK; Kim, JG; Lee, HW; Ohk, B; Seong, SJ; Sung, YK; Yoon, YR | 1 |
| Fujii, M; Harada, D; Harada, T; Hino, T; Ichinose, M; Inoue, A; Kuyama, S; Mori, Y; Nakagawa, T; Sugawara, S; Tanaka, H; Tsukita, Y; Watanabe, K | 1 |
| Ji, G; Meng, L; Wang, J; Wu, DX | 1 |
| Cai, GQ; Liao, GQ; Liu, S; Liu, WH; Qi, J; Xie, FJ; Yao, CY | 1 |
| Ebihara, A; Hua, Z; Oyakawa, T; Shiga, T | 1 |
| Fukuyama, Y; Iwano, M; Kawarai, S; Kayanuma, H; Maruo, T; Nishiyama, Y; Orito, K; Yoda, S | 1 |
| Chao, YJ; Chen, IS; Huang, HY; Liao, TK; Liu, IT; Shan, YS; Yen, CC; Yen, CJ | 1 |
| Doki, Y; Eguchi, H; Kitakaze, M; Miyoshi, N; Mizushima, T; Murata, K; Noura, S; Ohue, M; Takahashi, H; Tei, M; Uemura, M | 1 |
| Komatsu, Y; Saito, Y; Sugawara, M; Takekuma, Y; Takeuchi, S | 1 |
| Abdelmoneim, M; Bustos-Villalobos, I; Ichinose, T; Kasuya, H; Kikumori, T; Kodera, Y; Matsumura, S; Miyajima, N; Morimoto, D; Mukoyama, N; Naoe, Y; Ragab Eissa, I; Shibata, M; Takeuchi, D; Tanaka, M; Tsunoda, N | 1 |
| Fu, F; Huang, X; Liu, S; Wang, H; Wen, J | 1 |
| Funahara, H; Hiraki, K; Kikkawa, A; Matsumoto, S; Nakai, M | 1 |
| Eguchi, H; Fujii, T; Hattori, S; Hayashi, T; Higuchi, R; Hirooka, Y; Igarashi, H; Inoue, Y; Kawakatsu, S; Kitagawa, H; Kitano, M; Kuroki, T; Masamune, A; Nagakawa, Y; Ohba, A; Satoi, S; Shimizu, Y; Takami, H; Takeyama, Y; Tani, M; Tanno, S; Tomimaru, Y; Tsuji, Y; Unno, M; Yamamoto, T; Yamaue, H | 1 |
| An, MS; Baik, H; Jeong, JY; Kang, SH; Kim, KH; Oh, SH; Seo, SH | 1 |
8 review(s) available for tegafur and gimeracil
| Article | Year |
|---|---|
Modulation of 5-FU and its related compounds.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fluorouracil; Humans; Neoplasms; Pyridines; Tegafur; Uracil | 1997 |
Oral fluoropyrimidines in the treatment of colorectal cancer.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Enzyme Inhibitors; Fluorouracil; Humans; Oxidoreductases; Pyridines; Tegafur; Uracil | 1998 |
A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer.
Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Glutamates; Guanine; Humans; Pemetrexed; Platinum Compounds; Pyridines; Quinazolines; Tegafur; Thiophenes; Uracil | 1999 |
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.
Topics: Administration, Oral; Antineoplastic Agents; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Prodrugs; Pyridines; Tegafur; Treatment Outcome; Uracil | 2002 |
The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dosage Forms; Drug Administration Schedule; Drug Combinations; Drug Delivery Systems; Drug Evaluation, Preclinical; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Oxonic Acid; Prodrugs; Pyridines; Pyrimidines; Tegafur | 2004 |
The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Approval; European Union; Humans; Oxonic Acid; Practice Guidelines as Topic; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Tegafur; Treatment Outcome | 2011 |
Long-term survival in metastasized leiomyosarcoma: a case report and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colectomy; Disease-Free Survival; Doxorubicin; Female; Humans; Ifosfamide; Leiomyosarcoma; Lung Neoplasms; Oxonic Acid; Pyridines; Radiosurgery; Sigmoid Neoplasms; Tegafur; Treatment Outcome | 2015 |
Severe hypertriglyceridemia induced by S-1: Subsequent case series of four patients and further review of the literature.
Topics: Humans; Hyperlipidemias; Hypertriglyceridemia; Oxonic Acid; Pyridines; Tegafur; Triglycerides | 2021 |
22 trial(s) available for tegafur and gimeracil
| Article | Year |
|---|---|
An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Survival Analysis; Tegafur; Treatment Outcome | 1999 |
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.
Topics: Administration, Oral; Antineoplastic Agents; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Prodrugs; Pyridines; Tegafur; Treatment Outcome; Uracil | 2002 |
Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium.
Topics: Administration, Oral; Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Computer Simulation; Drug Combinations; Fluorouracil; Humans; Kidney; Kinetics; Models, Biological; Oxonic Acid; Pyridines; Renal Insufficiency; Tegafur; Time Factors; Uracil | 2007 |
Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2007 |
A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Disease Progression; Disease-Free Survival; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Oxonic Acid; Pyridines; Salvage Therapy; Survival Analysis; Tegafur; Thrombocytopenia | 2008 |
CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Aryl Hydrocarbon Hydroxylases; Asian People; Cytochrome P-450 CYP2A6; Drug Combinations; Female; Fluorouracil; Genotype; Humans; Male; Middle Aged; Mixed Function Oxygenases; Neoplasms; Oxonic Acid; Polymorphism, Genetic; Pyridines; Tegafur | 2008 |
[Curative effects of FTQ combined with cisplatin in treatment of advanced gastric cancer: a multicenter study].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans; Middle Aged; Oxonic Acid; Pyridines; Single-Blind Method; Stomach Neoplasms; Tegafur; Treatment Outcome | 2008 |
A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Drug Interactions; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Oxonic Acid; Pyridines; Tegafur | 2011 |
[Efficacy and side effects of combination therapy of oxaliplatin and S-1 for colorectal cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Female; Humans; Leukopenia; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Postoperative Period; Pyridines; Rectal Neoplasms; Remission Induction; Tegafur; Vomiting | 2011 |
Pharmacokinetic study of weekly (days 1-5) low-dose S-1 in patients with non-small-cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Female; Follow-Up Studies; Gas Chromatography-Mass Spectrometry; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Patient Compliance; Pyridines; Tegafur; Treatment Outcome | 2012 |
Pharmacokinetic study of S-1 in patients in whom inulin clearance was measured.
Topics: Aged; Antimetabolites, Antineoplastic; Area Under Curve; Creatinine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Glomerular Filtration Rate; Humans; Inulin; Kidney Function Tests; Male; Middle Aged; Oxonic Acid; Pyridines; Reference Values; Tegafur | 2012 |
Phase II study of oral S-1 plus cisplatin with bevacizumab for advanced non-squamous non-small cell lung cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pyridines; Tegafur; Treatment Outcome | 2013 |
Docetaxel/ TS-1 with radiation for unresectable squamous cell carcinoma of the esophagus--a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Taxoids; Tegafur | 2014 |
Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Drug Monitoring; Drug Screening Assays, Antitumor; Female; Gemcitabine; Hepatectomy; Humans; Male; Neutropenia; Postoperative Care; Pyridines; Tegafur; Treatment Outcome | 2014 |
The Clinical Evaluation of Tegafur Gimeracil Oteracil Combined with THP and DDP for Second-Line Treatment of Advanced Cardiac Carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Cisplatin; Doxorubicin; Female; Heart Neoplasms; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Tegafur | 2015 |
Postgastrectomy pharmacokinetic changes of S-1 in patients with localized advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Models, Biological; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2015 |
Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Drug Combinations; Esophageal Neoplasms; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Prospective Studies; Pyridines; Radiotherapy Dosage; Tegafur; Treatment Outcome; Young Adult | 2015 |
[Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Capsules; Dihydrouracil Dehydrogenase (NADP); Disease Progression; Humans; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur; Thymidine Phosphorylase | 2016 |
Randomized feasibility study of S-1 for adjuvant chemotherapy in completely resected Stage IA non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 0701.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Pyridines; Survival Rate; Tegafur; Treatment Outcome | 2016 |
Pharmacokinetic and bioequivalence study between two formulations of S-1 in Korean gastric cancer patients.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Chromatography, Liquid; Cross-Over Studies; Drug Compounding; Fluorouracil; Humans; Oxonic Acid; Pyridines; Republic of Korea; Stomach Neoplasms; Tandem Mass Spectrometry; Tegafur; Therapeutic Equivalency | 2019 |
Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Follow-Up Studies; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Prognosis; Prospective Studies; Pyridines; Survival Rate; Tegafur; Thymoma; Thymus Neoplasms | 2020 |
Anlotinib combined with SOX regimen (S1 (tegafur, gimeracil and oteracil porassium capsules) + oxaliplatin) in treating stage IV gastric cancer: study protocol for a single-armed and single-centred clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Oxonic Acid; Progression-Free Survival; Pyridines; Stomach Neoplasms; Tegafur; Treatment Outcome | 2020 |
54 other study(ies) available for tegafur and gimeracil
| Article | Year |
|---|---|
[Oral single-dose toxicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo].
Topics: Administration, Oral; Alopecia; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Diarrhea; Dogs; Drug Combinations; Female; Lethal Dose 50; Lymph Nodes; Male; Mice; Motor Activity; Oxonic Acid; Pyridines; Rats; Salivation; Spleen; Survival Rate; Tegafur; Thymus Gland | 1996 |
[Mutagenicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo].
Topics: Animals; Antimetabolites, Antineoplastic; Biotransformation; Cells, Cultured; Chromosome Aberrations; Cricetinae; Drug Combinations; Escherichia coli; Mutagenicity Tests; Oxonic Acid; Pyridines; Salmonella typhimurium; Tegafur | 1996 |
Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass sp
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Drug Combinations; Drug Stability; Fluorouracil; Gas Chromatography-Mass Spectrometry; Humans; Hydrogen-Ion Concentration; Kinetics; Magnetic Resonance Spectroscopy; Oxonic Acid; Pyridines; Sensitivity and Specificity; Tegafur | 1997 |
Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Colon; Diarrhea; Digestive System; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Fluorodeoxyuridylate; Fluorouracil; Ileum; Male; Oxonic Acid; Pyridines; Rats; Tegafur; Thymidylate Synthase | 2000 |
Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver.
Topics: Antimetabolites, Antineoplastic; Biotransformation; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Cytosol; Dose-Response Relationship, Drug; Fluorouracil; Humans; Kinetics; Liver; Microsomes, Liver; Pyridines; Tegafur; Thymidine Phosphorylase; Time Factors | 2001 |
Effects of 5-fluorouracil on the drug-metabolizing enzymes of the small intestine and the consequent drug interaction with nifedipine in rats.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Biotransformation; Calcium Channel Blockers; Cytochrome P-450 CYP1A1; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Activation; Enzyme Inhibitors; Fluorouracil; Glucuronosyltransferase; Glutathione Transferase; Immunoblotting; Intestinal Mucosa; Intestine, Small; Male; Microsomes; NADPH-Ferrihemoprotein Reductase; Nifedipine; Oxonic Acid; Pentosyltransferases; Pyridines; Rats; Rats, Inbred Strains; Tegafur | 2001 |
Complete response of highly advanced gastric cancer with peritoneal dissemination after new combined chemotherapy of S-1 and low-dose cisplatin: report of a case.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Gastroscopy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2001 |
A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Coumarins; Cytochrome P-450 CYP2A6; DNA Primers; DNA, Neoplasm; Drug Combinations; Escherichia coli; Genotype; Humans; Kinetics; Middle Aged; Mixed Function Oxygenases; Mutagenesis, Site-Directed; Oxonic Acid; Polymerase Chain Reaction; Polymorphism, Genetic; Pyridines; Recombinant Proteins; Stomach Neoplasms; Tegafur; Transfection | 2002 |
Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Line, Tumor; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Floxuridine; Fluorouracil; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Orotate Phosphoribosyltransferase; Oxonic Acid; Pyridines; Tegafur; Thymidine Phosphorylase; Treatment Outcome; Uracil; Xenograft Model Antitumor Assays | 2005 |
[TS-1 treatment for progressive gastric cancer in a patient on chronic dialysis--assessment of dosage regimen by monitoring blood concentrations of therapeutic drugs (TDM)].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Area Under Curve; Drug Administration Schedule; Drug Combinations; Drug Monitoring; Fluorouracil; Gastrectomy; Humans; Kidney Failure, Chronic; Male; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Renal Dialysis; Stomach Neoplasms; Tegafur | 2005 |
Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur; Time Factors | 2006 |
Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biological Availability; Drug Combinations; Female; Fluorouracil; Humans; Lymph Nodes; Male; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Peritoneum; Pyridines; Stomach Neoplasms; Tegafur | 2006 |
The first case of phenytoin intoxication associated with the concomitant use of phenytoin and TS-1, a combination preparation of tegafur, gimeracil, and oteracil potassium.
Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Drug Interactions; Humans; Male; Oxonic Acid; Phenytoin; Pyridines; Tegafur | 2008 |
[Marked effect of combination chemotherapy with tegafur-gimeracil-oteracil potassium and gemcitabine on a suspected case of pancreas cancer or gallbladder cancer metastasis to bone: further diagnosis of disseminated carcinomatosa of bone marrow recurrence
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Bone Marrow Neoplasms; Bone Neoplasms; Female; Gallbladder Neoplasms; Gastrectomy; Humans; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Radionuclide Imaging; Stomach Neoplasms; Tegafur; Time Factors; Treatment Failure | 2008 |
[A case of drug-induced interstitial pneumonia caused by TS-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Lung Diseases, Interstitial; Male; Oxonic Acid; Pyridines; Tegafur | 2008 |
Pharmacokinetic study of S-1.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Antimetabolites, Antineoplastic; Area Under Curve; beta-Alanine; Biological Availability; Clinical Trials as Topic; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Fasting; Fluorouracil; Food; Gastric Acidity Determination; Half-Life; Humans; Hydrogen-Ion Concentration; Oxonic Acid; Pantoprazole; Pyridines; Tegafur; Triazines; Uracil | 2009 |
Pharmacokinetics of 5-fluorouracil in elderly Japanese patients with cancer treated with S-1 (a combination of tegafur and dihydropyrimidine dehydrogenase inhibitor 5-chloro-2,4-dihydroxypyridine).
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Fluorouracil; Humans; Metabolic Clearance Rate; Neoplasms; Pyridines; Tegafur | 2009 |
Stereotactic body radiation therapy boost in locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Combined Modality Therapy; Disease-Free Survival; Dose Fractionation, Radiation; Female; Follow-Up Studies; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Positron-Emission Tomography; Pyridines; Radiosurgery; Retrospective Studies; Tegafur; Tomography, X-Ray Computed; Tumor Burden | 2009 |
Simultaneous determination of tegafur and gimeracil in human plasma by liquid chromatography/tandem mass spectrometry.
Topics: Analytic Sample Preparation Methods; Blood Chemical Analysis; Chromatography, Liquid; Humans; Limit of Detection; Linear Models; Pyridines; Reference Standards; Reproducibility of Results; Tandem Mass Spectrometry; Tegafur; Time Factors | 2009 |
Determination of tegafur, 5-fluorouracil, gimeracil and oxonic acid in human plasma using liquid chromatography-tandem mass spectrometry.
Topics: Chromatography, Liquid; Fluorouracil; Humans; Oxonic Acid; Pyridines; Reproducibility of Results; Tandem Mass Spectrometry; Tegafur | 2010 |
Concurrent chemoradiotherapy with S-1 for T2N0 glottic squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Combinations; Glottis; Humans; Kaplan-Meier Estimate; Laryngeal Neoplasms; Male; Middle Aged; Oxonic Acid; Pyridines; Radiation-Sensitizing Agents; Tegafur | 2010 |
Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Multiple Primary; Oxonic Acid; Pyridines; Remission Induction; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2011 |
Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; Drug Combinations; Fluorouracil; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Oxonic Acid; Pyridines; Radiation-Sensitizing Agents; Tegafur; Whole-Body Irradiation; Xenograft Model Antitumor Assays | 2010 |
The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Enzyme Inhibitors; Humans; Male; Mesothelioma; Mice; Mice, SCID; Neoplasm Proteins; Oxonic Acid; Pentosyltransferases; Pleural Neoplasms; Pyridines; Random Allocation; Survival Analysis; Tegafur; Thymidine Phosphorylase; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Chemosensitivity test for 5-fluorouracil and 5-chloro-2, 4-dihydroxypyridine predicts outcome of gastric cancer patients receiving S-1 postoperatively.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Postoperative Care; Predictive Value of Tests; Pyridines; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2010 |
[Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer].
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capsules; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur; Uracil | 2012 |
Spinal infarction related to the adjuvant chemotherapy for surgically resected non-small cell lung cancer: report of a case.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Female; Humans; Infarction; Lung Neoplasms; Oxonic Acid; Pneumonectomy; Pyridines; Spinal Cord; Tegafur; Treatment Outcome | 2013 |
Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin.
Topics: Acute Kidney Injury; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Hypertension; Lung Neoplasms; Middle Aged; Oxonic Acid; Pemetrexed; Plasma; Purpura, Thrombotic Thrombocytopenic; Pyridines; Quinazolines; Recombinant Proteins; Solubility; Taxoids; Tegafur; Thrombomodulin | 2013 |
Tegafur + gimeracil + oteracil. Just another fluorouracil precursor.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Oxonic Acid; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Tegafur | 2013 |
Treatment outcome of high-dose-rate interstitial radiation therapy for patients with stage I and II mobile tongue cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brachytherapy; Carboplatin; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intra-Arterial; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pyridines; Radiotherapy Dosage; Retrospective Studies; Tegafur; Tongue Neoplasms; Treatment Outcome | 2013 |
[Tegafur/gimeracil/oteracil (Teysuno), by oral administration].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Drug Interactions; Humans; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2013 |
Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Common Bile Duct Neoplasms; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Male; Medical Records; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Pyridines; Retrospective Studies; Tegafur; Treatment Outcome | 2014 |
[Case report of a patient with advanced and disseminated gastric carcinoma treated by s-1].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Czech Republic; Drug Combinations; Humans; Male; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur; Treatment Outcome | 2014 |
[A Case Report of Successful Chemotherapy with Tegafur/Gimeracil/Oteracil and Nab-Paclitaxel for Gastric Cancer with Chronic Renal Failure].
Topics: Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kidney Failure, Chronic; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Tegafur | 2015 |
Prediction of response to preoperative chemoradiotherapy and establishment of individualized therapy in advanced rectal cancer.
Topics: Chemoradiotherapy; Female; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Oxonic Acid; Preoperative Care; Pyridines; Random Allocation; Rectal Neoplasms; Tegafur | 2015 |
Tegafur gimeracil oter combined with oxaliplatin for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyridines; Tegafur | 2015 |
Surgical Resection for Solitary Myocardial Metastasis of Gastric Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Heart Neoplasms; Heart Ventricles; Humans; Magnetic Resonance Imaging; Male; Oxonic Acid; Positron Emission Tomography Computed Tomography; Pyridines; Radiopharmaceuticals; Remission Induction; Stomach Neoplasms; Tegafur | 2016 |
Acral lentiginosis associated with tegafur/gimeracil/oteracil (TS-1).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Drug Eruptions; Female; Foot Dermatoses; Hand Dermatoses; Humans; Lentigo; Male; Oxonic Acid; Pyridines; Tegafur | 2017 |
Prediction of Pathological Complete Response Using Endoscopic Findings and Outcomes of Patients Who Underwent Watchful Waiting After Chemoradiotherapy for Rectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Chemoradiotherapy; Colonoscopy; Digestive System Surgical Procedures; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Logistic Models; Lymph Node Excision; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Odds Ratio; Pyridines; Rectal Neoplasms; Rectum; Remission Induction; Retrospective Studies; Tegafur; Treatment Outcome; Watchful Waiting | 2017 |
Tegafur/gimeracil/oteracil (TS-1)-induced erythroderma with an extensive mucosal involvement and hand-foot syndrome.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dermatitis, Exfoliative; Drug Combinations; Drug Eruptions; Fluorouracil; Hand-Foot Syndrome; Humans; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds; Oxonic Acid; Pyridines; Tegafur | 2017 |
TS-1 (tegafur/gimeracil/oteracil)-induced systemic lupus erythematosus with skin lesions and anti-Sm antibody.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Male; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Renal Insufficiency; Tegafur | 2017 |
Effect of Sipjeondaebo-Tang on the Pharmacokinetics of S-1, an Anticancer Agent, in Rats Evaluated by Population Pharmacokinetic Modeling.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Drug Combinations; Drugs, Chinese Herbal; Fluorouracil; Herb-Drug Interactions; Humans; Male; Models, Biological; Oxonic Acid; Pyridines; Rats, Sprague-Dawley; Tegafur | 2017 |
Adjuvant Chemotherapy Versus Chemoradiotherapy Versus Surgery Alone for Early Gastric Cancer with One or Two Lymph Node Metastasis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gastrectomy; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxaliplatin; Oxaloacetates; Oxonic Acid; Pyridines; Radiotherapy Dosage; Stomach Neoplasms; Tegafur | 2018 |
[Pulmonary Metastasis of Gastric Cancer as Carcinomatous Lymphangiosis at Five and Half Years after Surgery;Report of a Case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Docetaxel; Fatal Outcome; Female; Humans; Lung Neoplasms; Middle Aged; Oxaliplatin; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2018 |
Huaier Granule Combined with Tegafur Gimeracil Oteracil Potassium Promotes Stage IIb Gastric Cancer Prognosis and Induces Gastric Cancer Cell Apoptosis by Regulating Livin.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Complex Mixtures; Disease-Free Survival; Female; Humans; Inhibitor of Apoptosis Proteins; Male; Middle Aged; Neoplasm Proteins; Potassium; Prognosis; Pyridines; Retrospective Studies; Stomach; Stomach Neoplasms; Survival Rate; Tegafur; Trametes | 2020 |
A Rare Case of Reversible Cardiac Dysfunction Associated with Tegafur/Gimeracil/Oteracil (S-1) Therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Drug Combinations; Humans; Male; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2021 |
Safety of alternate-day treatment with TS-1
Topics: Animals; Dog Diseases; Dogs; Drug Combinations; Oxonic Acid; Pilot Projects; Pyridines; Silicates; Stomach Neoplasms; Tegafur; Titanium | 2021 |
Surgery alone, adjuvant tegafur/gimeracil/octeracil (S-1), or platinum-based chemotherapies for resectable gastric cancer: real-world experience and a propensity score matching analysis.
Topics: Aged; Chemotherapy, Adjuvant; Drug Combinations; Humans; Middle Aged; Oxonic Acid; Propensity Score; Pyridines; Retrospective Studies; Stomach Neoplasms; Tegafur | 2021 |
Tolerability and safety of adjuvant chemoradiotherapy with S-1 after limited surgery for T1 or T2 lower rectal cancer.
Topics: Chemoradiotherapy, Adjuvant; Humans; Neoplasm Recurrence, Local; Oxonic Acid; Prospective Studies; Pyridines; Quality of Life; Rectal Neoplasms; Tegafur | 2021 |
S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model.
Topics: Animals; Antimetabolites, Antineoplastic; CD8-Positive T-Lymphocytes; Drug Combinations; Fluorouracil; Humans; Mice; Neoplasm Recurrence, Local; Oncolytic Viruses; Oxonic Acid; Pyridines; Tegafur; Triple Negative Breast Neoplasms | 2021 |
Application of Evidence-Based Nursing Intervention in the Treatment of Advanced Squamous Cell Carcinoma of the Lung by Erlotinib Combined with Tegafur, Gimeracil, and Oteracil Potassium and Its Influence on Quality of Life.
Topics: Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Evidence-Based Nursing; Humans; Lung; Oxonic Acid; Potassium; Pyridines; Quality of Life; Retrospective Studies; Tegafur | 2021 |
[Evaluation of Prognostic Factors in Patients with Relapse and Unresectable Biliary Tract Cancer, Treated with S-1 after Failure of Gemcitabine].
Topics: Biliary Tract Neoplasms; Deoxycytidine; Gemcitabine; Humans; Oxonic Acid; Prognosis; Pyridines; Recurrence; Retrospective Studies; Tegafur | 2022 |
Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Society based on real-world data.
Topics: Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Humans; Japan; Oxonic Acid; Pancreas; Pancreatic Neoplasms; Retrospective Studies; Tegafur | 2023 |
Doxifluridine versus Tegafur/Gimeracil/Oteracil (S-1) as adjuvant chemotherapy for patients with gastric cancer after gastrectomy: A propensity score-matched analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Gastrectomy; Humans; Neoplasm Staging; Oxonic Acid; Propensity Score; Retrospective Studies; Stomach Neoplasms; Tegafur | 2023 |